New Delhi, March 27 -- New Delhi,

Mumbai :

The Delhi High Court on Friday refused to allow the destruction of Dr Reddy's Laboratories Ltd's inventory of its generic semaglutide drug, Olymviq, while hearing Novo Nordisk's trademark infringement suit concerning its blockbuster brand Ozempic.

A bench of justice Jyoti Singh orally observed that destroying already manufactured stock of a diabetes drug would not be in the patients' interest. "We are dealing with a product consumed by diabetic patients. There can be nothing worse than destroying it," the court said, underscoring that public interest must weigh in such decisions.

The bench was responding to the Danish drugmaker's plea seeking directions for either destruction or repackaging o...